news
Experimental drug targets gene driving severe seizures in children
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
List view / Grid view
Target Validation
article
Rethinking antibody discovery in the age of automation
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
news
How one carbon atom is changing drug development
Researchers at the University of Oklahoma have found a way to improve drugs by adding just one carbon atom. This simple change could speed up drug discovery and lower costs.
article
Advancements in hit identification for membrane protein drug discovery
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
article
Refining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
news
Scientists identify key protein fuelling autoimmune attacks
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
news
Boltz-1: A new open-source AI tool for drug discovery
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
news
New collaboration targets key challenges in fibrosis treatment
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
article
Unleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
article
Targeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
news
Promising target for osteoporosis treatments found in new study
By identifying a mechanism behind bone strengthening in response to stress, researchers have found a possible new target for treating conditions that weaken bones.
news
Study identifies new therapeutic target for haematologic malignancies
Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
news
Gut-brain pathway metabolite involved in age-related cognitive decline, study shows
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
news
Antibody drug target identified for influenza viruses
Researchers have found a small subset of antibodies that target a site at the base of the influenza virus hemagglutinin protein.
article
Target safety assessments – identifying risk early
With an ever-increasing emphasis on minimising drug candidate attrition, scientists are focusing on target safety at earlier points in the research process. In this exclusive interview, Drug Target Review spoke with Dr Gordon Baxter, Chief Scientific Officer of Instem, to learn how target safety assessments can enable researchers to quickly…
